Expression and production of interleukin 10 in human myeloma cell lines.
Recent investigations of the cytokine network surrounding myeloma cells have disclosed the importance of gp130-related cytokines including interleukin (IL)-6 for myeloma cell survival and proliferation, identification of IL-10 as a growth factor for myeloma cells, the close relationship between IL-10 and the receptors for gp130-related cytokines, and the growth enhancement effect of IL-11 and IL-7 on myeloma cells. In this study, IL-10 production was observed in three out of seven human myeloma cell lines examined and five (including three producing lines) out of 10 lines exhibited mRNA expression of IL-10. The IL-10 mRNA expression was also enhanced in approximately one third of primary specimens, whereas the IL-10 receptor (R) expression was not changed compared with that of normal component marrow controls. However, reverse transcription-polymerase chain reaction (RT-PCR) assay of various cytokines and their receptors showed no particular association with IL-10-producing myeloma lines compared with non-producing lines. Supplementing exogenous IL-10 or neutralization of the IL-10 signal by anti-IL-10 monoclonal antibody (mAb) in a culture conditions did not significantly affect myeloma cell growth regardless of expression of IL-10 or its receptor (IL-10R). However, supplement of anti-IL-10 mAb caused upregulation of certain genes such as IL-11, leukaemia inhibitory factor receptor (LIFR) and syndecan-1 in IL-10R-expressing cell lines. These findings indicate that the cytokine network surrounding myeloma cells is complicated and variable. In addition, IL-10 may modify this network and the cellular biological properties of myeloma cells rather than cell proliferation.
Otsuki
T
T
Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama, Japan. takemi@med.kawasaki-m.ac.jp
Yamada
O
O
Yata
K
K
Sakaguchi
H
H
Kurebayashi
J
J
Yawata
Y
Y
Ueki
A
A
D000199:Actins / Q000235:genetics; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000235:genetics; D002455:Cell Division / Q000187:drug effects; D050822:Cytokine Receptor gp130; D016207:Cytokines / Q000235:genetics; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D017370:Interleukin-11 / Q000235:genetics; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology*; D011509:Proteoglycans / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis*; D018121:Receptors, Cytokine / Q000235:genetics; D018123:Receptors, Interleukin / Q000235:genetics; D053701:Receptors, Interleukin-10; D053606:Receptors, OSM-LIF; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D053668:Syndecan-1; D053667:Syndecans; D014407:Tumor Cells, Cultured
D000199:Actins; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D016207:Cytokines; C494199:IL6ST protein, human; D017370:Interleukin-11; C507840:LIFR protein, human; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008562:Membrane Glycoproteins; D011509:Proteoglycans; D012333:RNA, Messenger; D018121:Receptors, Cytokine; D018123:Receptors, Interleukin; D053701:Receptors, Interleukin-10; D053606:Receptors, OSM-LIF; D011994:Recombinant Proteins; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans; D016753:Interleukin-10; D050822:Cytokine Receptor gp130